Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen’s Sirturo: TB Milestone Awaits After Advisory Committee Hurdle

This article was originally published in The Pink Sheet Daily

Executive Summary

Important safety questions remain for what could be the first new tuberculosis drug in 40 years, and there was a lack of efficacy in the key subgroup of black patients.

You may also be interested in...



FDA Defends ‘Paradoxical’ Approval Of J&J’s TB Drug Sirturo In NEJM

Imbalance of deaths for bedaquiline patients despite efficacy on surrogate marker in Phase II study supporting accelerated approval is still unexplained with longer-term data. But with efficacy also still looking good, FDA defends approval for select population with high unmet need.

Emerging Markets Focused J&J’s Sirturo Approval Tied To Expansive Post-Marketing Study Program

The first drug approved for multi-drug resistant tuberculosis, Sirturo obtained accelerated approval based on data from two Phase II studies, but has a troubling safety database, including 10 deaths in the treatment arm of its Phase II program.

J&J’s Sirturo Approval Tied To Expansive Post-Marketing Study Program

The first drug approved for multi-drug resistant tuberculosis, Sirturo obtained accelerated approval based on data from two Phase II studies, but has a troubling safety database, including 10 deaths in the treatment arm of its Phase II program.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073545

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel